In our latest webinar, a number of expert practitioners discussed the latest findings of the use of 2.5% iPAAG (ArthramidVet) and upcoming advances.
EquiManagement has summarised the webinar in their blog below, which covers the latest findings on the use of 2.5% iPAAG (ArthramidVet®) for joint treatment, the mechanism of action, its treatment success rates, timeframe for success, and upcoming research.
Read the full article by EquiManagement HERE
Japan Racing Association (JRA) institute Laboratory for Racing Chemistry testing confirms Arthramid® Vet is free of Prohibited Substances in Japan Racing. To provide assurances to veterinarians in Japan, a representative…
Non-Pharmacological treatment offers veterinarians a better option for older and metabolic patients suffering from osteoarthritis (OA). Arthramid Vet’s 2.5% iPAAG technology is injected directly into the joint space providing lubrication…
Horses often show discomfort in a number of ways and it doesn’t always result in visual lameness or apparent discomfort. This was the case for Rolo, whose diagnosis wasn’t particularly…
